Log in

Principia Biopharma Stock Price, Forecast & Analysis (NASDAQ:PRNB)

$30.05
-0.57 (-1.86 %)
(As of 11/18/2019 04:42 AM ET)
Today's Range
$29.99
Now: $30.05
$30.89
50-Day Range
$26.54
MA: $30.83
$35.64
52-Week Range
$22.03
Now: $30.05
$42.34
Volume146,600 shs
Average Volume256,170 shs
Market Capitalization$985.34 million
P/E Ratio52.72
Dividend YieldN/A
Beta1.12
Principia Biopharma Inc, a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRNB
CUSIPN/A
CIKN/A
Phone650-416-7700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$69.14 million
Cash Flow$0.20 per share
Book Value$4.66 per share

Profitability

Net Income$18.17 million

Miscellaneous

Employees65
Market Cap$985.34 million
Next Earnings Date3/17/2020 (Estimated)
OptionableNot Optionable

Receive PRNB News and Ratings via Email

Sign-up to receive the latest news and ratings for PRNB and its competitors with MarketBeat's FREE daily newsletter.


Principia Biopharma (NASDAQ:PRNB) Frequently Asked Questions

What is Principia Biopharma's stock symbol?

Principia Biopharma trades on the NASDAQ under the ticker symbol "PRNB."

How were Principia Biopharma's earnings last quarter?

Principia Biopharma Inc (NASDAQ:PRNB) issued its quarterly earnings data on Tuesday, November, 5th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.85) by $0.08. Principia Biopharma had a negative return on equity of 11.95% and a net margin of 11.88%. View Principia Biopharma's Earnings History.

When is Principia Biopharma's next earnings date?

Principia Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, March 17th 2020. View Earnings Estimates for Principia Biopharma.

What price target have analysts set for PRNB?

3 Wall Street analysts have issued twelve-month price objectives for Principia Biopharma's stock. Their forecasts range from $42.00 to $57.00. On average, they expect Principia Biopharma's share price to reach $50.00 in the next year. This suggests a possible upside of 66.4% from the stock's current price. View Analyst Price Targets for Principia Biopharma.

What is the consensus analysts' recommendation for Principia Biopharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Principia Biopharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Principia Biopharma.

What are Wall Street analysts saying about Principia Biopharma stock?

Here are some recent quotes from research analysts about Principia Biopharma stock:
  • 1. According to Zacks Investment Research, "Principia Biopharma Inc. is a clinical stage biopharmaceutical company. It offers reversible covalent small molecule drugs for the treatment of cancers. The company's product pipeline consists of PRN1008, PRN1371 and PRN2246 which are in clinical stage. Principia Biopharma Inc. is based in San Francisco, United States. " (11/9/2019)
  • 2. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating and $45 target price after PRNB reported its 2Q19 financial and business update. We remain bullish ahead of what we view as a catalyst-rich 4Q19, with readouts expected for PRN1008 in both pemphigus vulgaris (PV) and immune thrombocytopenia purpura (ITP). We continue to think PRNB’s nuanced medicinal chemistry platform is under appreciated by the Street and, in our view, PRNB has developed a BTK inhibitor, PRN1008, with an improved safety profile allowing for use in autoimmune conditions which is something that has hindered previous BTKi’s. We believe PRN1008’s data generated to date, already suggest an improved safety profile and we think further proof-of-concept data in its two beachhead indications (PV and ITP) in 4Q19 should drive shares meaingfully higher." (8/11/2019)
  • 3. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $55 price target. Our current valuation is based on the PRN1008 opportunity in PV (86%) followed by incremental contribution from ITP (7%), PRN2246 for MS (5%), and PRN1371 for bladder cancer (2%). In PV, we project a 2022 and 2023 launch in the U.S. and E.U., based on a 50% projected chance of success and $1.0 billion and $570 million in peak sales, respectively. For ITP, we only model the U.S." (7/30/2019)

Has Principia Biopharma been receiving favorable news coverage?

News articles about PRNB stock have been trending very negative recently, InfoTrie reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Principia Biopharma earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future. View News Stories for Principia Biopharma.

Are investors shorting Principia Biopharma?

Principia Biopharma saw a decrease in short interest in the month of October. As of October 31st, there was short interest totalling 519,400 shares, a decrease of 29.0% from the September 30th total of 731,400 shares. Based on an average trading volume of 220,900 shares, the short-interest ratio is currently 2.4 days. Currently, 3.1% of the company's stock are sold short. View Principia Biopharma's Current Options Chain.

Who are some of Principia Biopharma's key competitors?

What other stocks do shareholders of Principia Biopharma own?

Who are Principia Biopharma's key executives?

Principia Biopharma's management team includes the folowing people:
  • Dr. Alan B. Colowick Ph.D., M.D., M.P.H., Exec. Chairman (Age 57)
  • Mr. Martin Babler, CEO & Director (Age 54)
  • Mr. Christopher Y. Chai, Chief Financial Officer (Age 52)
  • Ms. Stefani A. Wolff, Chief Devel. Officer (Age 57)
  • Dr. David M. Goldstein, Chief Scientific Officer (Age 53)

When did Principia Biopharma IPO?

(PRNB) raised $75 million in an initial public offering on Friday, September 14th 2018. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

Who are Principia Biopharma's major shareholders?

Principia Biopharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (1.11%), Alps Advisors Inc. (0.20%), Russell Investments Group Ltd. (0.10%) and Strs Ohio (0.06%). Company insiders that own Principia Biopharma stock include Daniel J Becker, David Goldstein, Leaf Ventures Ii LP New, Orbimed Advisors Llc, Plc Glaxosmithkline, Simeon George and Srinivas Akkaraju. View Institutional Ownership Trends for Principia Biopharma.

Which institutional investors are selling Principia Biopharma stock?

PRNB stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc. and Massachusetts Financial Services Co. MA. Company insiders that have sold Principia Biopharma company stock in the last year include David Goldstein, Leaf Ventures Ii LP New and Orbimed Advisors Llc. View Insider Buying and Selling for Principia Biopharma.

Which institutional investors are buying Principia Biopharma stock?

PRNB stock was purchased by a variety of institutional investors in the last quarter, including Strs Ohio and Russell Investments Group Ltd.. Company insiders that have bought Principia Biopharma stock in the last two years include Daniel J Becker, Leaf Ventures Ii LP New, Plc Glaxosmithkline, Simeon George and Srinivas Akkaraju. View Insider Buying and Selling for Principia Biopharma.

How do I buy shares of Principia Biopharma?

Shares of PRNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Principia Biopharma's stock price today?

One share of PRNB stock can currently be purchased for approximately $30.05.

How big of a company is Principia Biopharma?

Principia Biopharma has a market capitalization of $985.34 million and generates $69.14 million in revenue each year. The company earns $18.17 million in net income (profit) each year or $0.57 on an earnings per share basis. Principia Biopharma employs 65 workers across the globe.View Additional Information About Principia Biopharma.

What is Principia Biopharma's official website?

The official website for Principia Biopharma is http://www.principiabio.com/.

How can I contact Principia Biopharma?

Principia Biopharma's mailing address is 220 East Grand Avenue, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-416-7700 or via email at [email protected]


MarketBeat Community Rating for Principia Biopharma (NASDAQ PRNB)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  48 (Vote Outperform)
Underperform Votes:  60 (Vote Underperform)
Total Votes:  108
MarketBeat's community ratings are surveys of what our community members think about Principia Biopharma and other stocks. Vote "Outperform" if you believe PRNB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRNB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Featured Article: Outstanding Shares

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel